This week in therapeutics




Licensing status

Publication and contact information


Inflammatory disease

Heparan sulfate glycosaminoglycan (HSGAG)

In vitro studies identified heparan sulfate mimetics that could help treat inflammatory diseases. Sulfated HSGAGs regulate proinflammatory chemokines, but such compounds can have unwanted inhibitory effects on coagulation. HSGAG mimetics were designed from a disaccharide precursor core with tunable binding properties based on variable sulfation sequences. In vitro, a trisulfated mimetic antagonized heparin binding to the proinflammatory chemokine CC motif ligand 5 (RANTES; CCL5) without altering the coagulation cascade. Next steps could include testing the lead mimetics in animal models of inflammation.

SciBX 6(33); doi:10.1038/scibx.2013.896
Published online Aug. 29, 2013

Patent and licensing status unavailable

Sheng, G.J. et al. J. Am. Chem. Soc.; published online July 23, 2013;
Contact: Linda C. Hsieh-Wilson, California Institute of Technology and the Howard Hughes Medical Institute, Pasadena, Calif.